Today: 28 February 2026
Subscribe
Browse Category

ASX:CSL 20 August 2025 - 23 November 2025

CSL Limited (ASX:CSL): What You Need to Know Before the Market Opens on 24 November 2025

CSL Limited (ASX:CSL): What You Need to Know Before the Market Opens on 24 November 2025

CSL shares closed at A$178.85 on Friday, down about 36% year to date after profit downgrades and restructuring. The company is cutting 3,000 jobs, closing 22 US plasma centers, and has launched a US$1.5 billion US expansion and an on-market buy-back. Revenue and profit growth guidance for FY26 have been lowered. CSL has repurchased over 2 million shares as of 19 November.
23 November 2025
·
CSL Limited (ASX: CSL) pre‑open brief for 17 November 2025: Buy‑back in full swing, Seqirus spin‑off delayed, guidance cut — here’s what matters

CSL Limited (ASX: CSL) pre‑open brief for 17 November 2025: Buy‑back in full swing, Seqirus spin‑off delayed, guidance cut — here’s what matters

CSL closed at A$181.81 on Friday, down 0.07%, after a volatile period marked by a surprise guidance cut and delayed Seqirus demerger. Daily buy-back filings continued as CSL executes a A$750m program. At the October AGM, shareholders issued a second strike on pay but rejected a board spill. U.S. ADRs ended Friday at US$58.84, with after-hours trading slightly higher.
16 November 2025
·
CSL’s Vaccine Shock: Stock Plunges to 7-Year Low Amid Shareholder Revolt

CSL’s Vaccine Shock: Stock Plunges to 7-Year Low Amid Shareholder Revolt

CSL shares plunged up to 17% Tuesday after the company slashed its profit outlook and warned of a sharp drop in U.S. flu vaccinations. The sell-off erased billions from CSL’s value and forced it to delay the planned Seqirus spinoff. At its annual meeting, 42% of shareholders voted against executive pay, but a motion to spill the board failed. CSL now expects just 2–3% revenue growth for FY2026 and is cutting up to 3,000 jobs.
28 October 2025
·
Asia Stocks Rally as Gold Smashes Record Highs and IPO Frenzy Grips Markets

Wall Street Hits Record Highs as ASX Slumps – Gold Crashes, CSL Plunges 15% in Shock Divergence

Australia’s ASX 200 fell 0.5% to around 9,012 Tuesday, bucking Wall Street’s record highs. CSL and WiseTech Global each plunged about 15%, with CSL slashing its profit outlook and WiseTech hit by a police raid. Spot gold dropped over 3%, hammering local miners. Domino’s Pizza jumped 7% after reports of a possible Bain Capital takeover.
28 October 2025
·······
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 27.10.2025

CSL recorded a second strike on executive pay at its AGM, with over 40% of shareholders opposing, but the board survived a spill vote. Sany Heavy Industry raised HK$12.36 billion in a Hong Kong IPO, with shares rising over 3% on debut. NYSE posted listings for Solana and Litecoin ETFs as the SEC remains largely shut down. Investors brace for the Fed’s rate decision as hedging costs climb and market caution rises.
27 October 2025
·
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph

uniQure shares jumped over 150% on September 24, 2025, after its Huntington’s gene therapy slowed disease progression by 75% in a landmark trial. The company’s market value rose above $2.5 billion. uniQure plans to seek FDA approval in early 2026 and secured a $175 million credit facility to support commercialization. Cash reserves reached $377 million as of June 30, 2025.
24 September 2025
····
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

CSL will cut up to 15% of its workforce and spin off its vaccine unit, targeting $500–550 million in annual savings. Medtronic agreed to add two board members and form new committees after Elliott Investment Management took a major stake. Merck KGaA and Skyhawk Therapeutics announced a neurological drug pact worth up to $2 billion. Pfizer, Bristol Myers Squibb, and Regeneron reported improved Q2 2025 earnings.
20 August 2025
·····
1 2 3 4
Go toTop